© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 19, 2021
More and more individuals are becoming diagnosed with atrial fibrillation. But the research to halt this crisis is not quite there yet.
May 18, 2021
A survey at ACC 2021 showed 38% of cardiology professionals were burnt out during COVID-19. What factors in the field have already made it difficult to cope?
The high-risk patient population is under-represented in new research and agents. Why characteristics set it apart from other cardiovascular diseases?
The anticoagulant did not improve clinical outcomes when compared with prophylactic anticoagulation.
May 17, 2021
New data suggest 90 days following an initial ACS event is the greatest time of likelihood for another high-risk event. How can this inform cardiovascular research?
Marc Bonaca, MD, explains the value of new assessments made in the pivotal peripheral artery disease clinical trial.
A cardiologist and wellness expert discusses new findings showing more than one-third of her peers were burnt out from experiences during the pandemic.
The Duke investigators return to discuss the pivotal study of rivaroxaban in peripheral artery disease.
There is no clear threshold for consumption leading to an AFib event.
Patients with a preserved ejection fraction saw a significant reduction in risk for cardiovascular-related adverse events and mortality.